Germany to make J&J's COVID-19 vaccine available to all adults
A man receives a dose of the AstraZeneca COVID-19 vaccine in the Central Mosque in Ehrenfeld suburb, amid the coronavirus disease (COVID-19) pandemic, in Cologne, Germany, May 8, 2021. REUTERS/Thilo Schmuelgen
BERLIN (Reuters) - Germany is to make Johnson & Johnson's COVID-19 vaccine available to all adults, Health Minister Jens Spahn said on Monday, adding that they will be able to receive the shot on the advice of a doctor.
Europe's drug regulator backed J&J's vaccine last month after examining cases of a rare blood clotting issue in U.S. adults who received a dose. But it left it up to the European Union's member states to decide how to use it.
Germany's move to offer the J&J single-dose vaccine widely follows the lifting of restrictions last week on the AstraZeneca vaccine.
The AstraZeneca shot had been earmarked for people aged over 60 following similar reports of very rare but sometimes fatal clotting events in younger people, with women disproportionately affected.
The decisions reflect Germany's progress in vaccinating its seniors, Spahn said, adding he expected everyone aged 60 and above who wanted to be vaccinated to be offered a shot by late May or early June.
With millions of J&J doses due to arrive later in the second quarter of this year, it made sense to make the shot more widely available, he added.
Spahn forecast that 10 million doses of the J&J shot were expected to arrive in Germany by the end of the second quarter.
(Reporting by Caroline Copley and Douglas Busvine; Editing by Nick Macfie)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Altria tops first quarter sales on higher pricing, robust demand for smokeless alternatives
- Amazon is a more profitable company; Citi lifts price target
- Tractor Supply beats first-quarter profit estimates on easing costs
Create E-mail Alert Related Categories
FDA, General News, ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!